Sign Out
Use in pregnancy: There is limited information on the use of Rebif in pregnancy. Available data indicates that there may be an increased risk of spontaneous abortion. Initiation of treatment is contraindicated during pregnancy.
Women of childbearing potential should take appropriate contraceptive measures. If the patient becomes pregnant or plans to become pregnant while taking Rebif, she should be informed of the potential hazards, and discontinuation of therapy should be considered (see Toxicology under Actions). The risk of a severe relapse following discontinuation of Rebif in the event of pregnancy should be weighed against a possible increased risk of spontaneous abortion in patients with a high relapse rate before the initiation of treatment.
Use in lactation: It is not known whether Rebif is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or Rebif therapy.
